6 citations
,
February 2019 in “JAAD case reports” Acitretin helped improve hand mobility and skin condition in a patient.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
21 citations
,
January 2010 in “JOURNAL OF HEALTH SCIENCE” Abietic acid from pine resin can effectively inhibit testosterone 5α-reductase.
202 citations
,
June 2005 in “Aaps Pharmscitech” Lecithin organogels could be good for applying drugs to the skin because they are stable, safe, and can improve drug absorption.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
July 2025 in “Pharmaceutics” Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations
,
December 2021 in “Tropical Journal of Pharmaceutical Research” Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
18 citations
,
July 2016 in “British Journal of Dermatology” Cutaneous lupus erythematosus greatly reduces patients' quality of life.
August 2022 in “Case reports” Isotretinoin effectively treated a rare scalp condition, but careful drug monitoring and a dairy-free diet were important.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
182 citations
,
January 2000 in “Drug Development Research” Ethosomal carriers improve drug delivery through the skin better than traditional methods.
1 citations
,
August 2022 in “Frontiers in Medicine” ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
July 2025 in “Journal of Investigative Dermatology”
September 2021 in “Revista Interdisciplinar em Saúde” Oral isotretinoína effectively stabilizes frontal fibrosing alopecia.
2 citations
,
September 2017 in “Journal of Zoo and Wildlife Medicine” An addax had skin cancer that spread to lymph nodes and was euthanized.
1 citations
,
March 2023 in “Journal of the American College of Cardiology”
August 2018 in “Journal of The American Academy of Dermatology” Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
4 citations
,
January 2019 in “Elsevier eBooks” Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.